文献速递胸部肿瘤支持与姑息治疗

肺癌致癌基因靶向治疗、生育与妊娠

Lung Cancer Oncogene-Directed Therapy, Fertility, and Pregnancy.
PubMed 文献 · J Thorac Oncol · 2024-01-06

本文综述了EGFR、ALK和ROS1靶向治疗期间生育与妊娠的相关证据,涵盖胎盘灌注研究、药理特征、致突变性、动物胚胎-胎儿发育研究及病例报告。EGFR抑制剂可能降低女性生育力,克唑替尼和恩曲替尼具有体外致突变潜力,但11例暴露于EGFR或ALK酪氨酸激酶抑制剂的婴儿在4月龄至2岁时未出现实质性不良健康影响。部分晚期NSCLC患者的生育并非不可实现。

要点

  • EGFR抑制剂治疗期间可能因黄体减少而降低女性生育力。
  • 克唑替尼和恩曲替尼具有体外致突变潜力。
  • 11例暴露于EGFR或ALK酪氨酸激酶抑制剂的婴儿在4月龄至2岁时未出现实质性不良健康影响。

核心结论

  • 部分晚期NSCLC患者的生育可能并非不可实现。
  • 需要进一步探索靶向治疗在卵子捕获和妊娠中的影响及最佳时机。
  • 有必要对晚期NSCLC的生育问题进行更广泛的科学和社会讨论。

研究设计与样本

  • 叙述性综述,检索范围包括离体胎盘灌注研究、药理特征、致突变性、动物胚胎-胎儿发育研究以及EGFR、ALK或ROS1靶向治疗期间通往母亲之路、妊娠和卵子 retrieval 的病例报告。

主要发现

  • EGFR抑制剂治疗期间可能因黄体减少而降低女性生育力。
  • 动物中发现的潜在着床后丢失增加可能降低使用EGFR和ALK抑制剂女性的妊娠几率。
  • 克唑替尼和恩曲替尼具有体外致突变潜力。
  • 已记录到11例暴露于EGFR和ALK酪氨酸激酶抑制剂的婴儿在4月龄至2岁时未出现实质性不良健康影响。
  • 有两例接受克唑替尼治疗的女性成功进行妊娠代孕的报道。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Alterations in the highly actionable lung cancer oncogenes, EGFR, ALK, and ROS1, occur across the age spectrum. Pregnancy and plans for motherhood consequently overlap with diagnoses of advanced oncogene-driven NSCLC. Guidelines for cytotoxic agents and pregnancy are well established. Nevertheless, accessible data on targeted lung cancer therapy during pregnancy or egg retrieval has not been collated previously, nor have the issues of reproduction in the setting of specific oncogene-addicted advanced NSCLC been widely discussed. METHODS: We performed a narrative review of ex vivo placenta perfusion studies, pharmacologic characteristics, mutagenicity, animal embryo-fetal development studies, and case reports of pathways to motherhood, pregnancies, and egg retrieval while on EGFR-, ALK-, or ROS1-targeted therapy. RESULTS: EGFR inhibitors may reduce female fertility while on therapy owing to decrease in corpora lutea. Odds of pregnancy in women on EGFR and ALK inhibitors may be reduced owing to potential increase in postimplantation loss found in animals. Crizotinib and entrectinib exhibit in vitro mutagenic potential. Several effects on human pregnancies have been noted; however, 11 EGFR and ALK tyrosine kinase inhibitor-exposed infants have been documented free of substantial adverse health effects by ages 4 months to 2 years. Successful gestational surrogacy has been reported in two women treated with crizotinib. Adoption and termination approaches have also been undertaken by some patients. CONCLUSIONS: Reproduction may not be out of reach for some patients with advanced NSCLC. Additional explorations of the impact and optimal timing of targeted therapy in egg capture and pregnancy are needed. Wider scientific and societal discussion about the issues of reproduction in advanced NSCLC is warranted.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Simons E, Camidge DR. Lung Cancer Oncogene-Directed Therapy, Fertility, and Pregnancy. J Thorac Oncol. 2024. PMID: 38185202. doi:10.1016/j.jtho.2024.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。